VRCA - Verrica Pharmaceuticals Inc Stock Price, Fair Value and News

$7.52+0.79 (+11.74%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VRCA Price Action

Last 7 days

12.1%

Last 30 days

111.2%

Last 90 days

45.7%

Trailing 12 Months

-36.3%

VRCA RSI Chart

VRCA Valuation

Market Cap

71.4M

Price/Earnings (Trailing)

-2.74

Price/Sales (Trailing)

11.41

Price/Free Cashflow

-2.97

VRCA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VRCA Fundamentals

VRCA Revenue

Revenue (TTM)

7.6M

Rev. Growth (Yr)

145.35%

Rev. Growth (Qtr)

269.35%

VRCA Earnings

Earnings (TTM)

-26.0M

Earnings Growth (Yr)

98.8%

Earnings Growth (Qtr)

-234.31%

VRCA Profitability

Return on Equity

152.66%

Return on Assets

-63.61%

Free Cashflow Yield

-33.7%

VRCA Investor Care

Shares Dilution (1Y)

108.11%

Diluted EPS (TTM)

-2.81

VRCA Alerts

4 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	15.3M	23.1M	30.8M	0
2024	9.5M	13.9M	10.7M	7.6M
2023	0	7.7M	6.4M	5.1M
2022	11.3M	10.5M	9.8M	9.0M
2021	0	0	0	12.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

CEO	Mr. Ted White
WEBSITE	verrica.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	22

Verrica Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Verrica Pharmaceuticals Inc? What does VRCA stand for in stocks?

VRCA is the stock ticker symbol of Verrica Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Verrica Pharmaceuticals Inc (VRCA)?

As of Wed Dec 03 2025, market cap of Verrica Pharmaceuticals Inc is 71.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRCA stock?

You can check VRCA's fair value in chart for subscribers.

Is Verrica Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether VRCA is over valued or under valued. Whether Verrica Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Verrica Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRCA.

What is Verrica Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, VRCA's PE ratio (Price to Earnings) is -2.74 and Price to Sales (PS) ratio is 11.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRCA PE ratio will change depending on the future growth rate expectations of investors.